Private area
Contact Us
Total Visits
| Views | |
|---|---|
| Molecular ... | 164 |
Total Visits Per Month
| June 2025 | July 2025 | August 2025 | September 2025 | October 2025 | November 2025 | December 2025 | |
|---|---|---|---|---|---|---|---|
| Molecular ... | 12 | 8 | 3 | 1 | 3 | 24 | 7 |
File Visits
| Views | |
|---|---|
| molecular_clinical_determinants_response_resistance_rucaparib_recurrent_ovarian_cancer_treatment_ariel2_parts_1_2_2021.pdf | 181 |
| molecular_clinical_determinants_response_resistance_rucaparib_recurrent_ovarian_cancer_treatment_ariel2_parts_1_2_2021_material_suplementari1.pdf | 100 |
| molecular_clinical_determinants_response_resistance_rucaparib_recurrent_ovarian_cancer_treatment_ariel2_parts_1_2_2021_material_suplementari2.pdf | 45 |
Top country views
| Views | |
|---|---|
| United States | 79 |
| Brazil | 22 |
| Singapore | 13 |
| China | 12 |
| Spain | 6 |
| Germany | 4 |
| Vietnam | 3 |
| France | 2 |
| United Kingdom | 2 |
| Hong Kong | 2 |
Top cities views
| Views | |
|---|---|
| Chandler | 11 |
| Ashburn | 9 |
| Beijing | 8 |
| Singapore | 8 |
| Los Angeles | 7 |
| Buffalo | 5 |
| Barcelona | 3 |
| Curitiba | 2 |
| Frankfurt am Main | 2 |
| Hong Kong | 2 |
